NCT00697567View on ClinicalTrials.gov

Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 1992

Primary Completion Date

December 31, 1997

Study Completion Date

December 31, 1997

Conditions
Prophylaxis Herpes Simplex
Interventions
BIOLOGICAL

Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant

Intramuscular injection, 3 doses

BIOLOGICAL

Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant

Intramuscular injection, 3 doses

Trial Locations (1)

Unknown

GSK Clinical Trials Call Center, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00697567 - Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant | Biotech Hunter | Biotech Hunter